spacer
home > epc > autumn 2002 > moving through clinical phases ii and iii
PUBLICATIONS
European Pharmaceutical Contractor

Moving Through Clinical Phases II and III

This article is not a step-by-step guide to the well-defined stages of clinical development, as there are plenty of excellent texts on the definitions of each phase and all the regulatory requirements and implications. However, it is useful to review the impact of the individuals involved in the team assembled to convert the project to a product.

So let's move beyond the mechanical activities to the thought processes at each stage, the considerations and implications of the decision-making at each step, and how these are communicated to everyone involved.

In an ideal world the end of Phase I is reached with all the preclinical data completed to add to the first human safety and tolerance data. The project is then clearly mapped out through the stages leading to marketing approval for the chosen indication(s), with all the timelines neatly illustrated by whatever project management software is used. And then reality kicks in...


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Philip Guard, Vice-President of European Operations at Clinimetrics Research Associates Inc

Philip Guard has been in the pharmaceutical and biotech industry for over 16 years. Four years as a practicing veterinarian was followed by four years at Glaxo Animal Health.

He then joined Cortecs, a UK biopharmaceutical company (now Provalis), where he established both the clinical research and the project management groups and developed them into directorates within the company. His direct experience in clinical research covers a broad spectrum including therapeutics, biologicals and diagnostics. Philip joined Clinimetrics in 1999.

spacer
Philip Guard
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Northway Biotechpharma Celebrates 15 Years of Growth and Success

Vilnius, Lithuania, July 16, 2019 ─ Northway Biotechpharma, a leading biopharmaceutical contract development and manufacturing organization (CDMO), celebrates its 15th anniversary today. As a midsized CDMO, Northway Biotechpharma is able to provide flexibility and responsiveness backed by a strong foundation in science and technology. The company focuses on understanding its customers and meeting their specific needs without binding them to one single approach. It is able to react rapidly to unexpected project changes, adjusting timelines, capacities and other activities to meet its customers’ evolving needs. On average, Northway Biotechpharma has 25–30 development projects underway each year, ranging from gene cloning to final drug product manufacturing.
More info >>

White Papers

ECCRT

ECCRT

The European Centre for Clinical Research Training (ECCRT) is a professional clinical research training provider focusing on the transfer of implementable knowledge for the day-to-day activities of our participants whether being new to the industry, starters on the job, or seasoned professionals. Our mission is to facilitate Clinical Research professionals to excel in their job for the benefit of patients. We aim to achieve this by providing clinical research professionals with competencies to develop new therapies for patients quicker & more efficiently, without jeopardizing quality and safety.
More info >>

 
Industry Events

2020 Avoca Quality and Innovation Summit

3-4 June 2020, Amsterdam, The Netherlands

The 2020 Avoca Quality and Innovation Summit will take place 3-4 June 2020, in Amsterdam, The Netherlands.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement